Almirall, the global pharmaceutical company based in Barcelona, has announced the closing of a $15 million in Series C equity investment in Suneva Medical, Inc., an innovative aesthetics leader that markets Bellafill®. This product is the only dermal filler on the market that is FDA approved proven to be safe and effective for the correction of moderate to severe, atrophic, distensible facial acne scars on the cheek, in patients over the age of 21 years. The deal will give Almirall a position on the SunevaBoard of Directors as Suneva continues with its plans to be active in prescription, aesthetics and medicalised OTC Dermatology....show more
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.